The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor‐refractory obsessive‐compulsive disorder: a single‐blind, randomised study
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective: To investigate the comparative efficacy of aripiprazole and risperidone as augmenting agents in the treatment of obsessive‐compulsive disorder (OCD) patients who did not show a ≥35% decrease in the Yale‐Brown Obsessive‐Compulsive Scale (Y‐BOCS) after 12‐week monotherapy with selective serotonin reuptake inhibitors (SSRIs). Methods: The study consists of two different periods of treatment: a 12‐week prospective period to determine resistance to SSRI treatment and an 8‐week single‐blind addition period for refractory patients only. Ninety patients were randomly assigned to receive one of the SSRI treatments. Sixty‐nine patients (76.6%) completed the 12‐week SSRI monotherapy period. Forty‐one patients (59.4%) were considered refractory and were randomised to receive either risperidone (20 patients, 3 mgr daily) or aripiprazole (21 patients, 15 mgr daily) as augmentation to SSRI treatment. Sixteen patients (76.2%) in the aripiprazole group and 18 patients (84%) in the risperidone group completed the 8‐week treatment period. Results: Eight patients (50%) in aripiprazole and 13 patients (72.2%) in risperidone group met response criteria of Y‐BOCS decrease ≥35% at the end of the study. The risperidone group showed a significant improvement in Y‐BOCS obsession scores compared with aripiprazole. Conclusions: The present findings suggest that risperidone may be more effective than aripiprazole. Copyright © 2011 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705 · cited 1×
“All the adverse effects were recorded at every 2 weeks by means of the UKU Side Effect Rating Scale (Lingjaerde et al., 1987).”
MethodBloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635 · cited 4×
“In an adequate trial of an SRI, a less than 25–35% decrease in the Yale-Brown ObsessiveCompulsive Scale (Y-BOCS) score in patients with at least moderate obsessive compulsive symptom severity is usually considered partial response or non-response (Albert et al., 2002; Bloch et al., 2006; Denys, 2006; Pallanti and Quer…”
BackgroundInfluentialMcDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571 · cited 2×
“Studies with olanzapine, quetiapine and risperidone have shown that SGAs reduce obsessive compulsive (OC) symptoms in patients with OCD (McDougle et al., 2000; Atmaca et al., 2002; Bystritsky et al., 2004).”
BackgroundPallanti, S., & Quercioli, L. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.028 · Cited by 408 · cited 4×
“In an adequate trial of an SRI, a less than 25–35% decrease in the Yale-Brown ObsessiveCompulsive Scale (Y-BOCS) score in patients with at least moderate obsessive compulsive symptom severity is usually considered partial response or non-response (Albert et al., 2002; Bloch et al., 2006; Denys, 2006; Pallanti and Quer…”
BackgroundInfluential5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation
Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.921 · Cited by 370 · cited 1×
“A study conducted with PET has tested the bidirectional effect of SGAs and showed that SGAs cause high levels of 5-HT2 antagonism at low doses, whereas relatively high doses are required to produce significant D2 antagonism (Kapur et al., 1998).”
BackgroundBystritsky, A., Ackerman, D. L., Rosen, R. M., Vapnik, T., Gorbis, E., Maidment, K. M., & Saxena, S. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0418 · Cited by 220 · cited 1×
“Studies with olanzapine, quetiapine and risperidone have shown that SGAs reduce obsessive compulsive (OC) symptoms in patients with OCD (McDougle et al., 2000; Atmaca et al., 2002; Bystritsky et al., 2004).”
BackgroundPharmacotherapy of Obsessive-compulsive Disorder and Obsessive-Compulsive Spectrum Disorders
Denys, D. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.02.013 · Cited by 213 · cited 4×
“In the light of relevant literature (Albert et al., 2002; Denys, 2006), at the end of the 12- week SSRI treatment, patients who showed a reduction of less than 35% in the initial Y-BOCS scores were regarded as refractory.”
BackgroundInfluentialClomipramine, Clonazepam, and Clonidine Treatment of Obsessive-Compulsive Disorder
HEWLETT, W. A., VINOGRADOV, S., & AGRAS, W. S. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199212000-00008 · Cited by 129 · cited 1×
“Pharmacological options for SRI-refractory cases include increasing drug dose, changing to another SRI, or augmenting with lithium, clonazepam, buspirone and dopamine antagonists (Eisenberg and Asnis, 1985; Delgado et al., 1990; Hewlett et al., 1992; Pigott et al., 1992; McDougle et al., 1994).”
BackgroundKim, C.-H., Koo, M.-S., Cheon, K.-A., Ryu, Y.-H., Lee, J.-D., & Lee, H.-S. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1245-7 · Cited by 82 · cited 1×
“Kim et al. (2003) showed that OCD patients have higher dopamine transporter densities and lower dopamine D2 binding ratios, and Skapinakis et al. (2007) noted that these results are indirect evidences of increased dopaminergic activity in OCD.”
ResultDo antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms?
Sareen, J., Kirshner, A., Lander, M., Kjernisted, K. D., Eleff, M. K., & Reiss, J. P. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.03.011 · Cited by 79 · cited 2×
“…that 5-HT2 antagonism may induce or exacerbate OC symptoms, and that D2 antagonism may augment the anti-obsessional effect of 5-HT reuptake inhibitors, it might be expected that the anti-obsessional effect of SGAs may be more pronounced at higher doses (Ramasubbu et al., 2000; Sareen et al., 2004).”
Background
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“As adjunctive therapy for treatment-resistant OCD, risperidone was more effective than placebo (Level 1) [756-759] and as effective as olanzapine [760] and aripiprazole overall [755].”
BackgroundInfluentialEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv047 · Cited by 134
“Both other subgroups (≥8 weeks to 12 weeks and ≥12 weeks) were statistically significantly more efficacious than the <8 weeks group (for both comparisons: P = <.01) (supplementary Figure S8).”
BackgroundAlbert, U., Marazziti, D., Di Salvo, G., Solia, F., Rosso, G., & Maina, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666171222163645 · Cited by 90
Metadata
- Authors
- Selvi, Y., Atli, A., Aydin, A., Besiroglu, L., Ozdemir, P., & Ozdemir, O.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2011-01
- Volume
- 26
- Issue
- 1
- Pages
- 51-57
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2056932759
- Cited by
- 64
- References
- 10
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.